Oak Ridge Investments LLC Sells 22,331 Shares of Danaher Co. (NYSE:DHR)

Oak Ridge Investments LLC decreased its holdings in shares of Danaher Co. (NYSE:DHR) by 92.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,904 shares of the conglomerate’s stock after selling 22,331 shares during the quarter. Oak Ridge Investments LLC’s holdings in Danaher were worth $437,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in DHR. Decker Retirement Planning Inc. purchased a new stake in Danaher during the 4th quarter worth about $31,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher during the third quarter valued at about $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher in the third quarter worth about $40,000. FSA Wealth Management LLC purchased a new position in Danaher during the third quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC bought a new stake in Danaher during the 3rd quarter worth approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on DHR. TD Cowen boosted their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Robert W. Baird dropped their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Royal Bank of Canada cut their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Price Performance

DHR opened at $238.41 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70. The stock’s 50 day simple moving average is $234.85 and its 200 day simple moving average is $253.42. The firm has a market cap of $172.20 billion, a price-to-earnings ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.02 earnings per share. As a group, analysts predict that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s payout ratio is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.